[PDF] Top 20 Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
Has 10000 "Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients" found on our website. Below are the top 20 most common "Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients".
Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
... of prolonged-release oxycodone–naloxone (OXN-PR) daily dosages throughout the observation (expressed in ...and pain characteristics (three patients at day 7 [T7], one at day 14 ... See full document
11
Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
... with low-dose OXN-PR was well tolerated by the elderly patients of the present study, affected on average by multiple ...our patients were all naïve to strong opioids (a requirement for ... See full document
11
A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
... Cancer patients with moderate-to-severe chronic pain were con- secutively enrolled in two prospective 28-day trials, received either TDF or OXN-PR, and were assessed at baseline and after 7, 14, 21, ... See full document
11
Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
... that older patients with pain inadequately controlled by Step I analgesics of the WHO ladder and naive to opioids can be safely switched to low-dose Step III analgesics (strong ...for ... See full document
9
Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
... Abstract: Chronic pain is a highly disabling condition, which can significantly reduce patients’ quality of ...severe chronic pain is high in the general population, and it increases ... See full document
6
Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
... Fifty patients completed the ...of patients at T4 and 96% at T52 (P,0.0001). Pain intensity, measured on a 0–10 numerical rating scale, decreased from ...daily dose of oxycodone ... See full document
9
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
... many patients still do not achieve adequate symptom relief, as they fail to address the underlying opioid-related ...18,19 Naloxone is a peripherally acting opioid antagonist with low systemic ... See full document
11
Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
... Data for the post hoc analysis were obtained from a Phase III, double-blind, placebo-controlled, parallel-group, enriched- enrollment randomized-withdrawal (EERW), multicenter clinical study that evaluated the safety, ... See full document
9
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
... and patients using several different assessment instruments showed significantly greater quality of life improvements and significantly better tolerability under oxycodone/naloxone than under ... See full document
13
Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
... and tolerability among the various pretreatment groups was as expected: compared with those who were opioid-naïve or who had received prior therapy with weak opioids, patients on prior treatment with strong ... See full document
13
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
... (German pain study registry: 2012-0012-05; European Union Drug Regulating Authorities Clinical Trials [EudraCT]: 2012-001317-16), carried out in 88 centers in Germany, where a total of 901 patients ... See full document
17
Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
... RLS is a common neurologic disorder, and in light of an increasing aging population, it is possible that RLS preva- lence will increase in the coming years. The primary goal of RLS treatment is to reduce or eliminate ... See full document
9
Patient considerations in the use of tapentadol for moderate to severe pain
... a low affinity mu opioid receptor agonist and a norepinephrine reuptake ...in patients with hepatic and renal ...gastrointestinal tolerability and similar pain relief as compared to ... See full document
9
Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients
... documented patients were included in the effectiveness analysis (car- ried out by ...and tolerability analysis (Pharm-Soft Dr B Rodust GmbH, Ascheberg, ...in pain intensities and health state were ... See full document
8
Phenyramidol in acute conditions of lumbago, integumental pain and musculo-skeletal pain: an open label, noncomparative, multi-center study
... female patients, aged 18 to 60 years, with acute and sub-acute conditions of lumbago, integu- mental and musculoskeletal ...excluded patients with elevated levels of serum glutamic oxaloacetic transaminase ... See full document
7
<p>Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence</p>
... and tolerability of tapentadol PR for severe, chronic OA knee pain inadequately managed or left ...195 patients received tapentadol PR (50 – 250 mg bid) for a 5-week titration period, followed ... See full document
8
Original Article Efficacy and safety of titration with controlled-release oxycodone versus immediate-release morphine in patients with moderate cancer pain
... initial dose was 5 to 10 mg of IR morphine tablets, followed by correspond- ing treatment based on the pain intensity in patients at 1 h after medication whenever needed; 50 to 100% of morphine ... See full document
8
Considerations in selecting rapid-onset opioids for the management of breakthrough pain
... the patients were familiar with using oral medications, but only 2% of respondents had previous experience of using buccal medications (the OTFC lozenge on a stick), 16% had prior experience of nasally ... See full document
12
Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports
... daily), pain control was poor and wound care was limited by the intense ...care, pain and GI symptoms were assessed. The Brief Pain Inventory was used to assess the severity of pain and the ... See full document
5
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
... the efficacy of tapentadol in the management of ...descending pain inhibition in chronic pain patients with diabetic ...endogenous pain modulation: 1) conditioned pain ... See full document
11
Related subjects